NASDAQ:LGVN

Longeveron News Headlines

$5.59
+0.15 (+2.76 %)
(As of 05/7/2021 12:00 AM ET)
Add
Compare
Today's Range
$5.48
$5.64
50-Day Range
$5.44
$7.49
52-Week Range
$5.42
$12.48
Volume59,064 shs
Average Volume901,239 shs
Market Capitalization$105.97 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Headlines

Longeveron (NASDAQ LGVN) News Headlines Today

SourceHeadline
Longeveron Invited to Present at the Benzinga Global Small Cap ConferenceLongeveron Invited to Present at the Benzinga Global Small Cap Conference
finance.yahoo.com - May 5 at 12:39 PM
Longeveron Announces Successful Completion of Phase I/II Clinical Study of Lomecel-B Infusion in Aging Frailty Subjects to Improve Immune Response Following Influenza VaccinationLongeveron Announces Successful Completion of Phase I/II Clinical Study of Lomecel-B Infusion in Aging Frailty Subjects to Improve Immune Response Following Influenza Vaccination
finance.yahoo.com - April 15 at 12:52 PM
Longeveron Announces Positive Results of Phase I Clinical Study of Lomecel-B Cell Therapy for Alzheimer’s DiseaseLongeveron Announces Positive Results of Phase I Clinical Study of Lomecel-B Cell Therapy for Alzheimer’s Disease
finance.yahoo.com - April 13 at 12:04 PM
SmallCapsDaily: Longeveron Inc. Emerges as a True Blue Bio-Tech TitanSmallCapsDaily: Longeveron Inc. Emerges as a True Blue Bio-Tech Titan
finance.yahoo.com - April 12 at 10:52 AM
Longeveron Provides Corporate Update and Reports Fourth Quarter and Full Year 2020 Financial ResultsLongeveron Provides Corporate Update and Reports Fourth Quarter and Full Year 2020 Financial Results
finance.yahoo.com - March 30 at 7:56 AM
Longeveron Schedules 2020 Fiscal Year End Business Update Conference CallLongeveron Schedules 2020 Fiscal Year End Business Update Conference Call
feeds.benzinga.com - March 26 at 9:20 AM
Longeveron Inc. to Present at the Q1 Virtual Investor Summit on March 24Longeveron Inc. to Present at the Q1 Virtual Investor Summit on March 24
finance.yahoo.com - March 19 at 12:54 PM
Longeveron Inc. Announces Partial Exercise of Over-Allotment Option in Initial Public OfferingLongeveron Inc. Announces Partial Exercise of Over-Allotment Option in Initial Public Offering
finance.yahoo.com - March 15 at 7:08 PM
Longeveron’s Lomecel-B™ Approved by FDA for Compassionate Use for the Treatment of Child with Hypoplastic Left Heart Syndrome (HLHS)Longeveron’s Lomecel-B™ Approved by FDA for Compassionate Use for the Treatment of Child with Hypoplastic Left Heart Syndrome (HLHS)
finance.yahoo.com - March 11 at 9:04 AM
Longeveron and University of Miami Expand Exclusive License Agreement, and Enter into CRADA To Facilitate Future CollaborationsLongeveron and University of Miami Expand Exclusive License Agreement, and Enter into CRADA To Facilitate Future Collaborations
finance.yahoo.com - March 10 at 12:48 PM
Longeveron Expands Enrollment Criteria for its Phase 1 RECOVER Trial Evaluating Lomecel-B Infusion to Treat Acute Respiratory Distress Syndrome due to COVID-19 or Influenza InfectionLongeveron Expands Enrollment Criteria for its Phase 1 RECOVER Trial Evaluating Lomecel-B Infusion to Treat Acute Respiratory Distress Syndrome due to COVID-19 or Influenza Infection
finance.yahoo.com - March 5 at 1:25 PM
Longeveron Announces Successful Completion of Phase 2b Clinical Study of Lomecel-B Infusion to Treat Aging FrailtyLongeveron Announces Successful Completion of Phase 2b Clinical Study of Lomecel-B Infusion to Treat Aging Frailty
finance.yahoo.com - March 3 at 8:38 AM
Longeverons Allogeneic Cell Therapy Completes Early-Stage Study In Congenital Heart DefectLongeveron's Allogeneic Cell Therapy Completes Early-Stage Study In Congenital Heart Defect
finance.yahoo.com - February 24 at 10:15 PM
Longeveron Announces Successful Completion of Phase 1 Clinical Study of Lomecel-B Intramyocardial Injection in Hypoplastic Left Heart Syndrome PatientsLongeveron Announces Successful Completion of Phase 1 Clinical Study of Lomecel-B Intramyocardial Injection in Hypoplastic Left Heart Syndrome Patients
finance.yahoo.com - February 24 at 12:11 PM
Longeveron IncLongeveron Inc
reuters.com - February 24 at 1:42 AM
CEO of Longeveron Inc. to Present at the Intercontinental Summit on Aging & GerontologyCEO of Longeveron Inc. to Present at the Intercontinental Summit on Aging & Gerontology
finance.yahoo.com - February 19 at 9:55 AM
Longeveron Inc. Announces Pricing of an Upsized $26.6 Million Initial Public Offering and Nasdaq ListingLongeveron Inc. Announces Pricing of an Upsized $26.6 Million Initial Public Offering and Nasdaq Listing
finance.yahoo.com - February 15 at 11:52 AM
This page was last updated on 5/7/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.